Dabomb Protein Biotech Corporation(TW:6578)
NT$16.900.00 (0.00%)
TW:6578
Dabomb Protein Biotech Corporation financials statements
NT$16.90
At close:0.00 (0.00%)
Dabomb Protein Biotech Corporation (6578) Ratios
Dabomb Protein Biotech Corporation Ratios
TW:6578's free cash flow for Q2 2026 was NT$11.83M. For the 2026 fiscal year, TW:6578's free cash flow was decreased by NT$-458.00K and operating cash flow was NT$12.29M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.67 | 3.66 | 2.18 | 1.57 | 1.80 |
| Quick Ratio | 2.45 | 3.46 | 2.13 | 1.33 | 1.64 |
| Cash Ratio | 1.56 | 1.42 | 1.07 | 0.89 | 0.89 |
| Solvency Ratio | -0.27 | 0.11 | -0.08 | -0.03 | -0.05 |
| Operating Cash Flow Ratio | 0.20 | 0.27 | 0.02 | 0.09 | -0.20 |
| Short-Term Operating Cash Flow Coverage | 0.31 | 0.39 | 0.02 | 0.12 | -0.25 |
| Net Current Asset Value | NT$ 119.19M | NT$ 428.20M | NT$ 335.00M | NT$ -210.12M | NT$ -260.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.13 | 0.30 | 0.39 | 0.46 |
| Debt-to-Equity Ratio | 0.08 | 0.15 | 0.44 | 0.68 | 0.92 |
| Debt-to-Capital Ratio | 0.07 | 0.13 | 0.30 | 0.41 | 0.48 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.04 | 0.08 | 0.31 | 0.39 |
| Financial Leverage Ratio | 1.11 | 1.21 | 1.46 | 1.76 | 1.98 |
| Debt Service Coverage Ratio | -0.44 | 0.24 | -0.08 | -0.07 | -0.17 |
| Interest Coverage Ratio | -9.18 | -0.35 | -3.64 | -6.46 | -14.65 |
| Debt to Market Cap | 0.05 | 0.13 | 0.37 | 0.79 | 1.08 |
| Interest Debt Per Share | 1.07 | 2.60 | 8.00 | 12.99 | 19.18 |
| Net Debt to EBITDA | 2.61 | -2.43 | -1.46 | -19.42 | -10.32 |
| Profitability Margins | |||||
| Gross Profit Margin | 22.32% | 20.34% | 12.08% | 4.46% | 4.60% |
| EBIT Margin | -20.45% | 6.30% | -12.41% | -9.80% | -14.24% |
| EBITDA Margin | -7.19% | 10.35% | -6.76% | -3.57% | -8.67% |
| Operating Profit Margin | -9.11% | -0.54% | -7.79% | -9.80% | -14.24% |
| Pretax Profit Margin | -21.45% | 4.76% | -14.55% | -11.31% | -15.22% |
| Net Profit Margin | -22.42% | 3.44% | -14.83% | -10.30% | -13.27% |
| Continuous Operations Profit Margin | -22.42% | 3.44% | -14.83% | -10.30% | -13.27% |
| Net Income Per EBT | 104.52% | 72.43% | 101.93% | 91.05% | 87.19% |
| EBT Per EBIT | 235.39% | -881.29% | 186.93% | 115.48% | 106.83% |
| Return on Assets (ROA) | -6.33% | 0.88% | -4.07% | -3.49% | -4.67% |
| Return on Equity (ROE) | -7.01% | 1.07% | -5.95% | -6.14% | -9.26% |
| Return on Capital Employed (ROCE) | -2.79% | -0.16% | -2.86% | -4.00% | -6.02% |
| Return on Invested Capital (ROIC) | -2.64% | -0.10% | -2.17% | -3.16% | -4.51% |
| Return on Tangible Assets | -6.33% | 0.88% | -4.07% | -3.49% | -4.67% |
| Earnings Yield | -5.03% | 0.88% | -5.11% | -7.17% | -11.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.56 | 9.93 | 7.35 | 11.29 | 8.24 |
| Payables Turnover | 19.08 | 19.94 | 38.68 | 14.78 | 44.12 |
| Inventory Turnover | 12.62 | 7.90 | 16.70 | 7.85 | 11.92 |
| Fixed Asset Turnover | 0.37 | 0.54 | 0.66 | 0.49 | 0.53 |
| Asset Turnover | 0.28 | 0.26 | 0.27 | 0.34 | 0.35 |
| Working Capital Turnover Ratio | 1.00 | 0.75 | 1.41 | 2.86 | 2.55 |
| Cash Conversion Cycle | 58.10 | 64.68 | 62.11 | 54.15 | 66.65 |
| Days of Sales Outstanding | 48.29 | 36.77 | 49.69 | 32.34 | 44.29 |
| Days of Inventory Outstanding | 28.93 | 46.21 | 21.85 | 46.51 | 30.63 |
| Days of Payables Outstanding | 19.13 | 18.30 | 9.44 | 24.70 | 8.27 |
| Operating Cycle | 77.23 | 82.98 | 71.54 | 78.85 | 74.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.23 | 0.71 | 0.12 | 0.51 | -1.36 |
| Free Cash Flow Per Share | -0.29 | 0.26 | -0.23 | -0.01 | -11.59 |
| Dividend Paid and CapEx Coverage Ratio | 0.33 | 0.73 | 0.11 | 0.98 | -0.13 |
| Capital Expenditure Coverage Ratio | 0.44 | 1.57 | 0.34 | 0.98 | -0.13 |
| Operating Cash Flow Coverage Ratio | 0.22 | 0.28 | 0.02 | 0.04 | -0.07 |
| Operating Cash Flow to Sales Ratio | 0.05 | 0.14 | 0.02 | 0.05 | -0.09 |
| Free Cash Flow Yield | -1.53% | 1.30% | -1.11% | -0.07% | -66.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -19.90 | 116.47 | -19.58 | -14.00 | -9.09 |
| Price-to-Sales (P/S) Ratio | 4.46 | 3.92 | 2.90 | 1.44 | 1.20 |
| Price-to-Book (P/B) Ratio | 1.39 | 1.21 | 1.17 | 0.86 | 0.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -65.56 | 76.76 | -90.27 | -1387.54 | -1.51 |
| Price-to-Operating Cash Flow Ratio | 82.87 | 27.82 | 171.61 | 31.62 | -12.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | -1.01 | 2.81 | 0.35 | 0.01 |
| Enterprise Value Multiple | -59.40 | 35.39 | -44.41 | -59.64 | -24.21 |
| Enterprise Value | 1.32B | 1.24B | 1.15B | 923.87M | 987.84M |
| EV to EBITDA | -59.40 | 35.39 | -44.41 | -59.64 | -24.21 |
| EV to Sales | 4.27 | 3.66 | 3.00 | 2.13 | 2.10 |
| EV to Free Cash Flow | -62.80 | 71.83 | -93.35 | -2057.62 | -2.62 |
| EV to Operating Cash Flow | 79.39 | 26.03 | 177.46 | 46.88 | -22.32 |
| Tangible Book Value Per Share | 13.69 | 16.30 | 17.97 | 18.79 | 20.75 |
| Shareholders’ Equity Per Share | 13.70 | 16.30 | 17.98 | 18.79 | 20.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.05 | 0.28 | -0.02 | 0.09 | 0.13 |
| Revenue Per Share | 4.28 | 5.06 | 7.21 | 11.21 | 14.49 |
| Net Income Per Share | -0.96 | 0.17 | -1.07 | -1.15 | -1.92 |
| Tax Burden | 1.05 | 0.72 | 1.02 | 0.91 | 0.87 |
| Interest Burden | 1.05 | 0.76 | 1.17 | 1.15 | 1.07 |
| Research & Development to Revenue | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 |
| SG&A to Revenue | 0.26 | 0.16 | 0.16 | 0.16 | 0.16 |
| Stock-Based Compensation to Revenue | -0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Income Quality | -0.25 | 2.96 | -0.12 | -0.40 | 0.62 |
Currency in TWD
